TransMedics to Report First Quarter 2021 Financial Results on May 4, 2021
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX) will release its first-quarter financial results on May 4, 2021, after market close. A conference call will follow at 4:30 p.m. ET for investors to discuss the results. The company specializes in advanced organ transplant technologies aimed at improving donor organ quality and viability assessment for heart, lung, and liver transplants. Investors can access the call by phone or via the live webcast on the company's website.
Positive
- Leadership in portable extracorporeal warm perfusion for organ transplantation.
- Technologies aimed at improving organ quality and viability assessments.
Negative
- None.
News Market Reaction – TMDX
In the trading session that priced this news, TMDX gained 13.26%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Tuesday, May 4, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for domestic callers or (763) 488-9145 for international callers, followed by Conference ID: 1172894. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-report-first-quarter-2021-financial-results-on-may-4-2021-301273113.html
SOURCE TransMedics Group, Inc.